Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 8/20 | 0.44 |
| ▸ | DRD2 | P14416 | 8/20 | 0.44 |
| ▸ | HTR1A | P08908 | 7/20 | 0.44 |
| ▸ | DRD1 | P21728 | 7/20 | 0.44 |
| ▸ | DRD4 | P21917 | 7/20 | 0.44 |
| ▸ | DRD5 | P21918 | 7/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | ELOVL6 | Q9H5J4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1980422 | 0.93 | NPC1 (0.45) | DRD3DRD2HTR1ADRD1DRD4 | |
| SCHEMBL1983279 | 0.81 | LMNA (0.45) | — | |
| SCHEMBL1978853 | 0.79 | HTR1A (0.39) | DRD3DRD2HTR1ADRD1DRD4 | |
| SCHEMBL1980009 | 0.79 | ALDH1A1 (0.46) | — | |
| SCHEMBL14243776 | 0.75 | NPC1 (0.44) | NPC1EPHX2 | |
| SCHEMBL1979757 | 0.75 | ALDH1A1 (0.48) | NPC1 | |
| SCHEMBL1982673 | 0.74 | LMNA (0.50) | DRD2 | |
| SCHEMBL1013368 | 0.73 | HTR6 (0.43) | DRD3 | |
| SCHEMBL6434004 | 0.72 | HDAC8 (0.45) | DRD3DRD2HTR1ADRD1DRD4 | |
| SCHEMBL6437900 | 0.72 | HDAC8 (0.45) | DRD3DRD2HTR1ADRD1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2509945-B1 | 4-(AZACYCLOALKYL)-BENZENE-1,3-DIOL DERIVATIVES AS TYROSINASE INHIBITORS AND THEIR SYNTHESIS AND USE THEREOF | GALDERMA RES & DEV (FR) | 2014-03-05 | — | — | EP | claimed |
| US-20120323012-A1 | 4-(AZACYCLOALKYL) -BENZENE-1,3-DIOL DERIVATIVES AS TYROSINASE INHIBITORS AND THEIR SYNTHESIS AND USE THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-12-20 | — | — | US | claimed |
| EP-2509945-A1 | 4- (AZACYCLOALKYL) -BENZENE-1, 3 -DIOL DERIVATIVES AS TYROSINASE INHIBITORS AND THEIR SYNTHESIS AND USE THEREOF | Galderma Research & Development (FR) | 2012-10-17 | — | — | EP | claimed |
| WO-2011070080-A1 | 4- (AZACYCLOALKYL) -BENZENE-1, 3 -DIOL DERIVATIVES AS TYROSINASE INHIBITORS AND THEIR SYNTHESIS AND USE THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-06-16 | — | — | WO | claimed |
| EP-2509945-B1 | 4-(AZACYCLOALKYL)-BENZENE-1,3-DIOL DERIVATIVES AS TYROSINASE INHIBITORS AND THEIR SYNTHESIS AND USE THEREOF | GALDERMA RES & DEV (FR) | 2014-03-05 | — | — | EP | disclosed |
| US-20120323012-A1 | 4-(AZACYCLOALKYL) -BENZENE-1,3-DIOL DERIVATIVES AS TYROSINASE INHIBITORS AND THEIR SYNTHESIS AND USE THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-12-20 | — | — | US | disclosed |
| EP-2509945-A1 | 4- (AZACYCLOALKYL) -BENZENE-1, 3 -DIOL DERIVATIVES AS TYROSINASE INHIBITORS AND THEIR SYNTHESIS AND USE THEREOF | Galderma Research & Development (FR) | 2012-10-17 | — | — | EP | disclosed |
| WO-2011070080-A1 | 4- (AZACYCLOALKYL) -BENZENE-1, 3 -DIOL DERIVATIVES AS TYROSINASE INHIBITORS AND THEIR SYNTHESIS AND USE THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120323012-A1 | 4-(AZACYCLOALKYL) -BENZENE-1,3-DIOL DERIVATIVES AS TYROSINASE INHIBITORS AND THEIR SYNTHESIS AND USE THEREOF | TYR, DDT, TH | DRD3 1001/4885DRD2 1210/4885HTR1A 2399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.